Scientists Have Managed to Create a Mouse Model for Idiopathic Pulmonary Fibrosis
Free-Photos / Pixabay

Scientists Have Managed to Create a Mouse Model for Idiopathic Pulmonary Fibrosis

According to a story from EurakAlert!, a group of researchers from the University of Pennsylvania School of Medicine have achieved a major breakthrough for idiopathic pulmonary fibrosis research that will…

Continue Reading Scientists Have Managed to Create a Mouse Model for Idiopathic Pulmonary Fibrosis

A Treatment for Paroxysmal Nocturnal Hemoglobinuria Was Accepted for Priority Review

According to a story from Morningstar, the company Alexion Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) has agreed to review their Biologics Licensing Application for their…

Continue Reading A Treatment for Paroxysmal Nocturnal Hemoglobinuria Was Accepted for Priority Review
Ehlers-Danlos Society Dazzles at the Zebra Ball
Performance of "It's Our Time," a song about the search for an EDS diagnosis.

Ehlers-Danlos Society Dazzles at the Zebra Ball

Recently, the Ehlers-Danlos Society held its second annual Zebra Ball at the EDS World Learning Conference in Baltimore, Maryland. The event fundraised for further support and awareness of Ehlers-Danlos syndrome…

Continue Reading Ehlers-Danlos Society Dazzles at the Zebra Ball
Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug
stevepb / Pixabay

Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug

  Takeda Pharmaceutical Company Limited and Ovid Therapeutics have released an overview of the clinical development program for TAK-935/OV935, an investigational drug that is being developed as a potential anti-epileptic…

Continue Reading Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug

New Partnership May Have Implications for Those with Dravet, Alzheimer’s, Epilepsy, and More

According to Newswire, the two companies, BioMotiv and Cure Network Dolby Acceleration Partners (CNDAP) partnered up together in order to create small molecules that can potentially treat various neurological disorders, including…

Continue Reading New Partnership May Have Implications for Those with Dravet, Alzheimer’s, Epilepsy, and More
FDA Grants Orphan Drug Designation to Onspira Therapeutics’ Investigational Interleukin-1 Receptor Antagonist for the Treatment of Bronchiolitis Obliterans
InspiredImages / Pixabay

FDA Grants Orphan Drug Designation to Onspira Therapeutics’ Investigational Interleukin-1 Receptor Antagonist for the Treatment of Bronchiolitis Obliterans

According to a story from Business Wire, the biopharmaceutical company Onspira Therapeutics recently announced that its investigational therapy OSP-101 was recently granted Orphan Drug designation by the US Food and…

Continue Reading FDA Grants Orphan Drug Designation to Onspira Therapeutics’ Investigational Interleukin-1 Receptor Antagonist for the Treatment of Bronchiolitis Obliterans
Experimental Duchenne Muscular Dystrophy Drug Gets Multiple Designations From the FDA
jarmoluk / Pixabay

Experimental Duchenne Muscular Dystrophy Drug Gets Multiple Designations From the FDA

According to a story from Globe Newswire, the biotechnology company Wave Life Sciences recently announced that its investigational product WVE-210201 has received both Rare Pediatric disease designation and Orphan Drug…

Continue Reading Experimental Duchenne Muscular Dystrophy Drug Gets Multiple Designations From the FDA
Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa
LaCasadeGoethe / Pixabay

Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa

Two companies, GtreeBNT and YuYang DNU, will collaborate in a joint venture to develop the investigational drug RGN-137 for the treatment of epidermolysis bullosa. For more details, you can read…

Continue Reading Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa